ENDRA Life Sciences (NASDAQ:NDRA) Issues Quarterly Earnings Results

ENDRA Life Sciences (NASDAQ:NDRA) issued its quarterly earnings results on Friday. The company reported ($1.75) EPS for the quarter, beating analysts’ consensus estimates of ($2.67) by $0.92, Zacks reports.

ENDRA Life Sciences Stock Performance

Shares of NASDAQ:NDRA traded up $0.13 during trading hours on Friday, hitting $6.70. 25,634 shares of the company’s stock traded hands, compared to its average volume of 91,418. The company has a market cap of $5.03 million, a price-to-earnings ratio of -0.20 and a beta of -0.09. ENDRA Life Sciences has a 52 week low of $2.90 and a 52 week high of $11.96. The company’s fifty day simple moving average is $5.53 and its two-hundred day simple moving average is $4.93.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of ENDRA Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, ENDRA Life Sciences currently has an average rating of “Hold” and a consensus target price of $50.00.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.